Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes
Table 1
Serum pancreatic functional marker, clinical effect of CRT, and pancreatic morphological features before and after CRT.
The 264 patients with PDAC who were enrolled in CRT protocol from February 2005 to May 2016
Before CRT
After CRT
P value
Albumin (g/dl) (n=260)
3.9 (2.5-4.7)
3.8 (2.2-4.7)
0.025
Total cholesterol (mg/dl) (n=210)
162 (36-326)
158 (74-251)
0.114
Amylase (U/l) (n=220)
74 (16-651)
59 (9-808)
<0.001
CA19-9 (U/ml)
180.2 (0.1-26666.4)
43.5 (0.1-9476)
<0.001
TS (mm)
58.1 (13.6-137.6)
55.6 (19.8-312.1)
<0.001
MPDD (mm)
4.0 (0.3-15.5)
3.6 (0.5-16.3)
<0.001
PPV (ml)
34.8 (3.4-97.8)
25.2 (3.6-85.2)
<0.001
The 44 patients with PDAC who had apoAII isoforms measured from February 2015 to May 2016
Before CRT
After CRT
P value
Albumin (g/dl)
3.9 (3.1-4.6)
3.7 (2.7-4.4)
0.038
Total lymphocyte (mm3)
1400 (480-3860)
805 (220-2060)
<0.001
Total cholesterol (mg/dl) (n=27)
155 (103-199)
167 (99-219)
0.178
Prognostic nutritional index
45.6 (32.9-57.4)
41.5 (31.1-52)
<0.001
Amylase (U/l) (n=36)
71 (28-248)
59 (18-249)
0.346
CA19-9 (U/ml)
229.7 (0.1-26666.4)
28.5 (0.1-2228.5)
<0.001
TS (mm)
60.9 (23.4-137.6)
56.5 (25.7-119.8)
0.002
MPDD (mm)
3.7 (1.0-12.5)
3.7 (0.7-11.5)
0.511
PPV (ml)
37.0 (15.3-82.9)
29.5 (8.1-69.1)
<0.001
CRT: chemoradiotherapy, TS: tumor size (sum of short and long axis), MPDD: diameter of main pancreatic duct, and PPV: pancreatic parenchymal volume excluding tumor volume
